Special Issue

From Prion Molecular Mechanisms to Targeted Therapeutics: Informing the Broader Proteinopathy Paradigm

Message from the Guest Editor

The contribution of prion researchers to science goes far beyond discovering a model for a rare group of neurodegenerative disorders. The prion field has been the canary in the coal mine for the neurodegenerative disease research community. Prion researchers provided the first definitive evidence that proteins alone self-propagate by converting endogenous protein into a pathogenic isoform that disrupts cellular homeostasis and drives progressive neurodegeneration.

As prion researchers expand their interests to other proteinopathies, the opportunities to discover shared mechanisms of pathogenesis multiply, which is advancing the neurodegeneration research field significantly. The breakthroughs have contributed to the understanding of the pathogenic mechanisms and the development of therapeutic strategies across the spectrum of neurodegenerative proteinopathies.

Guest Editor

Dr. Patricia Aguilar-Calvo
Killion Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1719 6th Avenue South, Birmingham, AL 35294, USA

Deadline for manuscript submissions

31 August 2026

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed

mdpi.com/si/272603

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI